KRRO (Korro Bio) Total Liabilities: $63.99 Mil (As of Mar. 2026)


KRRO Korro Bio Inc KRRO
6 GF Score
Price $12.87
! 4 Warning Signs
View Full Analysis

What is Korro Bio Total Liabilities?

Korro Bio KRRO +1.34% 6 Total Liabilities is $63.99 Mil as of Mar. 2026. GuruFocus rates KRRO with a GF Score™ of 6/100. The stock has 4 warning signs investors should review.

Korro Bio's Total Liabilities for the quarter that ended in Mar. 2026 was $63.99 Mil.

Korro Bio's quarterly Total Liabilities declined from Sep. 2025 ($62.52 Mil) to Dec. 2025 ($62.07 Mil) but then increased from Dec. 2025 ($62.07 Mil) to Mar. 2026 ($63.99 Mil).

Korro Bio's annual Total Liabilities increased from Dec. 2023 ($51.75 Mil) to Dec. 2024 ($65.83 Mil) but then declined from Dec. 2024 ($65.83 Mil) to Dec. 2025 ($62.07 Mil).

Korro Bio Total Liabilities Historical Data

* Premium members only.

The historical data trend for Korro Bio's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Korro Bio Total Liabilities Chart

Korro Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
169.78 172.77 51.75 65.83 62.07

Korro Bio Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.25 65.32 62.52 62.07 63.99
KRRO
6GF Score
Korro Bio Inc KRRO
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Korro Bio Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Korro Bio's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=11.937+(40.814+1.481
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+7.835+0+0)
=62.07

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=113.506-51.439
=62.07

Korro Bio's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=14.787+(40.084+1.462
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+7.656+0+0)
=63.99

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=183.622-119.633
=63.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $63.99 Mil mean?
Korro Bio (KRRO) has a Total Liabilities of $63.99 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Korro Bio and its competitors.
Is Korro Bio's Total Liabilities too high?
Korro Bio's current Total Liabilities is $63.99 Mil. Overall, Korro Bio has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Korro Bio's Total Liabilities compare to LENZ and ANTX?
Korro Bio's Total Liabilities of $63.99 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Korro Bio and its competitors. Korro Bio's current Total Liabilities is $63.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Korro Bio stock overvalued right now?
Korro Bio (KRRO) has a current Total Liabilities of $63.99 Mil. The current Total Liabilities is $63.99 Mil. Korro Bio's overall GF Score™ is 6/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Korro Bio (KRRO), the current Total Liabilities is $63.99 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Korro Bio Business Description

Address 60 First Street, 2nd Floor, Suite 250, Cambridge, MA, USA, 02141
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
6GF Score

Get the complete analysis for KRRO

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.87
Price